Apex Treasury Corp

# Signal Note: Driehaus Initiates Apex Therapeutics Position **Key Signal:** Growth-focused Driehaus Capital established a $2.5M position (375K shares) in Apex Therapeutics, signaling conviction in the company's pipeline advancement. Apex is advancing APX5009 (selective PI3K delta inhibitor) in autoimmune/inflammatory conditions and APX3330 (NOXO1 inhibitor) in solid tumors, with near-term catalysts expected from ongoing Phase 2 studies through 2024-2025. **Relevance:** Entry by a dedicated biotech allocator suggests confidence in clinical readout timing or commercial potential, though the relatively modest position size ($2.5M) indicates measured risk exposure rather than conviction-level bet.